Dantrolene is neuroprotective in Huntington's disease transgenic mouse model

Molecular Neurodegeneration

Volumn 6, Issue 1, 2011, Pages

  Chen, Xi ^a   Wu, Jun ^a   Lvovskaya, Svetlana ^a,b   Herndon, Emily ^a   Supnet, Charlene ^a,b   Bezprozvanny, Ilya ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b PETER THE GREAT ST PETERSBURG POLYTECHNIC UNIVERSITY   (Russian Federation)

Author keywords

neuroprotection

Indexed keywords

CAFFEINE; CALCIUM ION; DANTROLENE; GLUTAMIC ACID; NEURON SPECIFIC NUCLEAR PROTEIN; RYANODINE RECEPTOR; CALCIUM; CENTRAL MUSCLE RELAXANT; CENTRAL STIMULANT AGENT; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CONTROLLED STUDY; FEMALE; GAIT; HUNTINGTON CHOREA; MALE; MOUSE; NERVE CELL CULTURE; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; TRANSGENIC MOUSE; WILD TYPE; ANIMAL; APOPTOSIS; CELL CULTURE; CORPUS STRIATUM; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; METABOLISM; MOTOR ACTIVITY; NERVE CELL; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

MUS; MUS MUSCULUS;

ANIMALS; APOPTOSIS; CAFFEINE; CALCIUM; CALCIUM SIGNALING; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM STIMULANTS; CORPUS STRIATUM; DANTROLENE; DISEASE MODELS, ANIMAL; GLUTAMIC ACID; HUNTINGTON DISEASE; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; MUSCLE RELAXANTS, CENTRAL; NEURONS; NEUROPROTECTIVE AGENTS;

EID: 82055164052     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-6-81     Document Type: Article

References (50)

1. Neuropathological classification of Huntington's disease. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr, J Neuropathol Exp Neurol 1985 44 6 559 577 10.1097/00005072-198511000-00003 2932539 (Pubitemid 16196286)
2. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. Bauer PO, Nukina N, J Neurochem 2009 110 6 1737 1765 10.1111/j.1471-4159.2009.06302.x 19650870
3. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1, 4, 5) triphosphate receptor type 1. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I, Neuron 2003 39 2 227 239 10.1016/S0896-6273(03)00366-0 12873381 (Pubitemid 36897546)
4. Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Tang TS, Slow E, Lupu V, Stavrovskaya IG, Sugimori M, Llinas R, Kristal BS, Hayden MR, Bezprozvanny I, Proc Natl Acad Sci USA 2005 102 7 2602 2607 10.1073/pnas.0409402102 15695335 (Pubitemid 40279423)
5. Neuroprotective effects of inositol 1, 4, 5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model. Tang TS, Guo C, Wang H, Chen X, Bezprozvanny I, J Neurosci 2009 29 5 1257 1266 10.1523/JNEUROSCI. 4411-08.2009 19193873
6. Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment. Wu J, Shih HP, Vigont V, Hrdlicka L, Diggins L, Singh C, Mahoney M, Chesworth R, Shapiro G, Zimina O, et al. Chem Biol 2011 18 6 777 793 10.1016/j.chembiol.2011.04.012 21700213
7. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease. Zhang H, Li Q, Graham RK, Slow E, Hayden MR, Bezprozvanny I, Neurobiol Dis 2008 31 1 80 88 10.1016/j.nbd.2008.03.010 18502655
8. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington's disease. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA, Neuron 2002 33 6 849 860 10.1016/S0896-6273(02)00615-3 11906693 (Pubitemid 34246352)
9. Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Zeron MM, Fernandes HB, Krebs C, Shehadeh J, Wellington CL, Leavitt BR, Baimbridge KG, Hayden MR, Raymond LA, Mol Cell Neurosci 2004 25 3 469 479 10.1016/j.mcn.2003.11.014 15033175 (Pubitemid 38366412)
10. Striatal neuronal apoptosis is preferentially enhanced by NMDA receptor activation in YAC transgenic mouse model of Huntington disease. Shehadeh J, Fernandes HB, Zeron Mullins MM, Graham RK, Leavitt BR, Hayden MR, Raymond LA, Neurobiol Dis 2006 21 2 392 403 10.1016/j.nbd.2005.08.001 16165367 (Pubitemid 43099862)
11. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Milnerwood AJ, Raymond LA, Trends Neurosci 2010 33 11 513 523 10.1016/j.tins.2010.08.002 20850189
12. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Okamoto SI, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, et al. Nat Med 2009
13. Deranged neuronal calcium signaling and Huntington disease. Bezprozvanny I, Hayden MR, Biochem Biophys Res Commun 2004 322 4 1310 1317 10.1016/j.bbrc.2004.08.035 15336977 (Pubitemid 39164659)
14. Calcium signaling and neurodegenerative diseases. Bezprozvanny I, Trends Mol Med 2009 15 3 89 100 10.1016/j.molmed.2009.01.001 19230774
15. Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine, and calcium. Miller BR, Bezprozvanny I, Future Neurology 2010 5 735 756 10.2217/fnl.10.41 21977007
16. Role of Inositol 1, 4, 5-Trishosphate Receptors in Pathogenesis of Huntington's Disease and Spinocerebellar Ataxias. Bezprozvanny I, Neurochem Res 2011
17. The endoplasmic reticulum: a multifunctional signaling organelle. Berridge MJ, Cell Calcium 2002 32 5-6 235 249 10.1016/S0143416002001823 12543086 (Pubitemid 36175747)
18. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2. Liu J, Tang TS, Tu H, Nelson O, Herndon E, Huynh DP, Pulst SM, Bezprozvanny I, J Neurosci 2009 29 29 9148 9162 10.1523/JNEUROSCI.0660-09.2009 19625506
19. Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3. Chen X, Tang TS, Tu H, Nelson O, Pook M, Hammer R, Nukina N, Bezprozvanny I, J Neurosci 2008 28 48 12713 12724 10.1523/JNEUROSCI.3909-08.2008 19036964
20. Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Wu J, Tang T, Bezprozvanny I, Neurosci Lett 2006 407 3 219 223 10.1016/j.neulet.2006.08.036 16959411 (Pubitemid 44402868)
21. Evaluation of Dimebon in cellular model of Huntington's disease. Wu J, Li Q, Bezprozvanny I, Mol Neurodegener 2008 3 1 15 10.1186/1750-1326-3-15 18939977
22. Ginsenosides protect striatal neurons in a cellular model of Huntington's disease. Wu J, Jeong HK, Bulin SE, Kwon SW, Park JH, Bezprozvanny I, J Neurosci Res 2009 87 8 1904 1912 10.1002/jnr.22017 19185022
23. Dantrolene prevents glutamate cytotoxicity and Ca2+ release from intracellular stores in cultured cerebral cortical neurons. Frandsen A, Schousboe A, J Neurochem 1991 56 3 1075 1078 10.1111/j.1471-4159.1991.tb02031.x 1671584 (Pubitemid 21922725)
24. Kainic acid-induced seizures and brain damage in the rat: role of calcium homeostasis. Berg M, Bruhn T, Frandsen A, Schousboe A, Diemer NH, J Neurosci Res 1995 40 5 641 646 10.1002/jnr.490400509 7602615
25. NMDA receptor-dependent excitotoxicity: the role of intracellular Ca2+ release. Mody I, MacDonald JF, Trends Pharmacol Sci 1995 16 10 356 359 10.1016/S0165-6147(00)89070-7 7491714
26. Dantrolene is cytoprotective in two models of neuronal cell death. Wei H, Perry DC, J Neurochem 1996 67 6 2390 2398 8931471 (Pubitemid 26392509)
27. Increased vulnerability of hippocampal neurons to excitotoxic necrosis in presenilin-1 mutant knock-in mice. Guo Q, Fu W, Sopher BL, Miller MW, Ware CB, Martin GM, Mattson MP, Nat Med 1999 5 1 101 106 10.1038/4789 9883847 (Pubitemid 29051006)
28. Neuroprotective effects of early vs. late administration of dantrolene in experimental status epilepticus. Niebauer M, Gruenthal M, Neuropharmacology 1999 38 9 1343 1348 10.1016/S0028-3908(99)00059-3 10471088 (Pubitemid 29333150)
29. Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation. Schneider I, Reverse D, Dewachter I, Ris L, Caluwaerts N, Kuiperi C, Gilis M, Geerts H, Kretzschmar H, Godaux E, et al. J Biol Chem 2001 276 15 11539 11544 10.1074/jbc.M010977200 11278803
30. Dantrolene protects neurons against kainic acid induced apoptosis in vitro and in vivo. Popescu BO, Oprica M, Sajin M, Stanciu CL, Bajenaru O, Predescu A, Vidulescu C, Popescu LM, J Cell Mol Med 2002 6 4 555 569 10.1111/j.1582-4934.2002.tb00454.x 12611640 (Pubitemid 44146434)
31. Dantrolene inhibits NMDA-induced 45Ca uptake in cultured cerebellar granule neurons. Makarewicz D, Zieminska E, Lazarewicz JW, Neurochem Int 2003 43 4-5 273 278 10.1016/S0197-0186(03)00012-3 12742069 (Pubitemid 36561278)
32. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. Tang TS, Chen X, Liu J, Bezprozvanny I, J Neurosci 2007 27 30 7899 7910 10.1523/JNEUROSCI.1396-07.2007 17652581 (Pubitemid 47173323)
33. Tetrabenazine is neuroprotective in Huntington's disease mice. Wang H, Chen X, Li Y, Tang TS, Bezprozvanny I, Mol Neurodegener 2010 5 18 10.1186/1750-1326-5-18 20420689
34. Expanded Polyglutamine-Binding Peptoid as a Novel Therapeutic Agent for Treatment of Huntington's Disease. Chen X, Wu J, Luo Y, Liang X, Supnet C, Kim MW, Lotz GP, Yang G, Muchowski PJ, Kodadek T, et al. Chem Biol 2011 18 9 1113 1125 10.1016/j.chembiol.2011.06.010 21944750
35. Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts. Zhang H, Das S, Li QZ, Dragatsis I, Repa J, Zeitlin S, Hajnoczky G, Bezprozvanny I, BMC Neurosci 2008 9 1 38 10.1186/1471-2202-9-38 18412970 (Pubitemid 351676653)
36. Azumolene inhibits a component of store-operated calcium entry coupled to the skeletal muscle ryanodine receptor. Zhao X, Weisleder N, Han X, Pan Z, Parness J, Brotto M, Ma J, J Biol Chem 2006 281 44 33477 33486 10.1074/jbc.M602306200 16945924 (Pubitemid 46036729)
37. Dantrolene: mechanisms of neuroprotection and possible clinical applications in the neurointensive care unit. Muehlschlegel S, Sims JR, Neurocrit Care 2009 10 1 103 115 10.1007/s12028-008-9133-4 18696266
38. Effects of dantrolene on extracellular glutamate concentration and neuronal death in the rat hippocampal CA1 region subjected to transient ischemia. Nakayama R, Yano T, Ushijima K, Abe E, Terasaki H, Anesthesiology 2002 96 3 705 710 10.1097/00000542-200203000-00029 11873048 (Pubitemid 34193513)
39. Early postischemic dantrolene-induced amelioration of poly(ADP-ribose) polymerase-related bioenergetic failure in neonatal rat brain slices. Tasker RC, Sahota SK, Cotter FE, Williams SR, J Cereb Blood Flow Metab 1998 18 12 1346 1356 9850147 (Pubitemid 28559682)
40. Neuronal apoptosis induced by pharmacological concentrations of 3-hydroxykynurenine: characterization and protection by dantrolene and Bcl-2 overexpression. Wei H, Leeds P, Chen RW, Wei W, Leng Y, Bredesen DE, Chuang DM, J Neurochem 2000 75 1 81 90 10854250 (Pubitemid 30418172)
41. Tumor necrosis factor induces apoptosis in hepatoma cells by increasing Ca(2+) release from the endoplasmic reticulum and suppressing Bcl-2 expression. Kim BC, Kim HT, Mamura M, Ambudkar IS, Choi KS, Kim SJ, J Biol Chem 2002 277 35 31381 31389 10.1074/jbc.M203465200 12077131 (Pubitemid 34968937)
42. Alzheimer's presenilin mutation sensitizes neural cells to apoptosis induced by trophic factor withdrawal and amyloid beta-peptide: involvement of calcium and oxyradicals. Guo Q, Sopher BL, Furukawa K, Pham DG, Robinson N, Martin GM, Mattson MP, J Neurosci 1997 17 11 4212 4222 9151738 (Pubitemid 27220612)
43. The cell death-promoting gene DP5, which interacts with the BCL2 family, is induced during neuronal apoptosis following exposure to amyloid beta protein. Imaizumi K, Morihara T, Mori Y, Katayama T, Tsuda M, Furuyama T, Wanaka A, Takeda M, Tohyama M, J Biol Chem 1999 274 12 7975 7981 10.1074/jbc.274.12.7975 10075695 (Pubitemid 29144268)
44. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. Rothstein JD, Kuncl RW, J Neurochem 1995 65 2 643 651 7616220
45. The cytoprotective effects of dantrolene: a ryanodine receptor antagonist. Inan S, Wei H, Anesth Analg 2010 111 6 1400 1410 10.1213/ANE.0b013e3181f7181c 20861418
46. Role of presenilins in neuronal calcium homeostasis. Zhang H, Sun S, Herreman A, De Strooper B, Bezprozvanny I, J Neurosci 2010 30 25 8566 8580 10.1523/JNEUROSCI.1554-10.2010 20573903
47. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Krause T, Gerbershagen MU, Fiege M, Weisshorn R, Wappler F, Anaesthesia 2004 59 4 364 373 10.1111/j.1365-2044.2004.03658.x 15023108 (Pubitemid 38489297)
48. Therapeutic prospects for spinocerebellar ataxia type 2 and 3. Bezprozvanny I, Klockgether T, Drugs of the Future 2010 34 12 991 999
49. Deranged Calcium Signaling in Purkinje Cells and Pathogenesis in Spinocerebellar Ataxia 2 (SCA2) and Other Ataxias. Kasumu A, Bezprozvanny I, Cerebellum 2010
50. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Slow EJ, van Raamsdonk J, Rogers D, Coleman SH, Graham RK, Deng Y, Oh R, Bissada N, Hossain SM, Yang YZ, et al. Hum Mol Genet 2003 12 13 1555 1567 10.1093/hmg/ddg169 12812983 (Pubitemid 36857303)